Literature DB >> 16221374

A "snapshot" of an ovarian cancer clinical practice: evidence for viewing the malignancy as a "chronic disease".

Maurie Markman.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16221374     DOI： 10.1007/s11912-005-0001-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  10 in total

1.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

Authors:  Andreas du Bois; Hans-Joachim Lück; Werner Meier; Hans-Peter Adams; Volker Möbus; Serban Costa; Thomas Bauknecht; Barbara Richter; Matthias Warm; Willibald Schröder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch; Günther Emons; Uwe Wagner; Walther Kuhn; Jacobus Pfisterer
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

Review 2.  Second-line treatment of ovarian cancer.

Authors:  M Markman; M A Bookman
Journal:  Oncologist       Date:  2000

3.  Management of ovarian cancer in patients older than 80 years of Age.

Authors:  N G Cloven; A Manetta; M L Berman; M F Kohler; P J DiSaia
Journal:  Gynecol Oncol       Date:  1999-04       Impact factor: 5.482

4.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

5.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

Review 6.  Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.

Authors:  Allan Covens; Mark Carey; Peter Bryson; Shailendra Verma; Michael Fung Kee Fung; Mary Johnston
Journal:  Gynecol Oncol       Date:  2002-04       Impact factor: 5.482

7.  Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.

Authors:  Vijaya Sundararajan; Dawn Hershman; Victor R Grann; Judith S Jacobson; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  Treatment of advanced ovarian carcinoma in the elderly.

Authors:  D L Marchetti; S B Lele; R L Priore; M E McPhee; M M Hreshchyshyn
Journal:  Gynecol Oncol       Date:  1993-04       Impact factor: 5.482

9.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

10.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.